Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Ototoxicity in Cystic Fibrosis Patients Receiving Intravenous Tobramycin for Acute Pulmonary Exacerbation

Ototoxicity in Cystic Fibrosis Patients Receiving Intravenous Tobramycin for Acute Pulmonary Exacerbation

Resource Type

CF Research News

Authors

Emily Harruff, Jonathan Kil, Maria Gabriela Tupayachi Ortiz, Daniel Dorgan, Raksha Jain, Elizabeth A Poth, Robert C Fifer, Yun Jin M Kim, Angela G Shoup, Patrick A Flume

References

J Cyst Fibros. 2020 Dec 16;S1569-1993(20)30930-9. doi: 10.1016/j.jcf.2020.11.020.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

Aminoglycoside [3]
Hearing loss [4]
Ototoxicity [5]
Tinnitus [6]
Tobramycin [7]

Date

Wednesday, December 16, 2020

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [8]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/ototoxicity-cystic-fibrosis-patients-receiving-intravenous

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-20-00304R1_FINAL_Harruff_260121.pdf [2] https://pubmed.ncbi.nlm.nih.gov/33341407/ [3] https://www.ecfs.eu/research-article-keywords/aminoglycoside [4] https://www.ecfs.eu/research-article-keywords/hearing-loss [5] https://www.ecfs.eu/research-article-keywords/ototoxicity [6] https://www.ecfs.eu/research-article-keywords/tinnitus [7] https://www.ecfs.eu/research-article-keywords/tobramycin [8] https://www.ecfs.eu/resource-guideline-type/other-guidelines